A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...
Clinical Trials Arena on MSN
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...
Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...
The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ...
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results